ONCR || Melanoma & Skin Cancers

Nivolumab extends survival in advanced melanoma

Posted on: 12/03/2014 - 14:15

An immunomodulator that targets the PD-1 pathway effected sustained remission in 31% of patients who took it for advanced melanoma. Remission lasted a median of 2 years, with 1- and 2-year overall...

Field of Interest: Oncology
Type: News Item

IBD linked to increased risk of certain cancers

Posted on: 01/02/2014 - 05:01

Immunosuppressive therapies for inflammatory bowel disease do not appear to be implicated in the increased risk for melanomas and hematologic malignancies seen in these patients, based on the results...

Field of Interest: Gastroentero...
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness